One last reminder - DEADLINE MAY 1 @4 pm
Frequently asked questions:
Q: Do students need an official, sealed transcript?
A: No. Submit a web transcript or a scanned official transcript.
If the committee needs further clarification, it will ask for it later.
Q: Do Nancy Hettie Clark applicants need to submit sealed letters
form advisors under separate cover?
A: Students/postdocs may attach the letter directly to the email
with their application if advisors agree. Alternatively, advisors my email
separately to networking(a)manitobaneuroscience.ca
<mailto:networking@manitobaneuroscience.ca> with the name of the applicant
in the subject header.
As first announced on March 1, the MNN wishes to remind all Manitoba
scientists of our newly-created awards for trainee conference travel and a
distinguished lectureship. The deadline is May 1, 2017. Details of each
award are as follows:
NANCY HETTIE CLARK TRAINEE TRAVEL AWARDS.
Applications are now being accepted until MAY 1, 2017 for conferences taking
place between May 1, 2017 and April 30, 2018. There will normally be at
least 2 awards of $700 each, annually. The intent is for one award to go to
a Ph.D. student and the other to a postdoctoral fellow, although awards in
any trainee category can be made based on the quality and availability of
applicants.
A complete application package consists of the following, sent by email to
networking(a)manitobaneuroscience.ca
<mailto:networking@manitobaneuroscience.ca> by May 1:
* A graduate level academic transcript (students only)
* Current curriculum vitae (CV)
* Two-page (maximum) description of the research presented, the
proposed conference and the type of presentation
* Support letter from the primary research advisor with: (a) a merit
assessment of the candidate and project; and (b) confirmation that there is
a commitment to cover all eligible travel expenses less the award value
Confirmation that the abstract is accepted and will be presented will also
be required when it becomes available. Awards may be combined with other
travel awards up to but not exceeding the total cost of travel to the chosen
conference/workshop. Recipients must claim all eligible travel costs in
accordance with the appropriate policies and procedures of the University of
Manitoba.
Eligible trainees are considered to be either Ph.D. students or postdoctoral
fellows enrolled in or appointed at the University of Manitoba. Student
candidates must be enrolled as full-time Ph.D. students in the Faculty of
Graduate Studies, University of Manitoba, and have a cumulative graduate
grade point average of 3.5 or greater. Postdoctoral fellow candidates must
be within the first five years their doctoral degree and have full-time
appointments at the University of Manitoba or an affiliated hospital or
institute. Research Associates are not eligible. Candidates must
demonstrate excellent research performance and potential in a
neurosciences-related discipline. Candidates must also demonstrate they
will disseminate research results that reflect a high-quality contribution
by The University of Manitoba.
VIKTOR HAVLICEK MEMORIAL NEUROSCIENCE LECTURESHIP.
Applications are now being accepted until MAY 1, 2017 for a visit and
lecture to take place between April 1, 2018 and March 31, 2019. There will
normally be one award of $3000, made biannually. Applications for the next
Lectureship will be accepted in 2019 for 2020/2021 fiscal year.
Nominations must be made by a faculty member but trainees and staff are
encouraged to suggest names to their advisors. Faculty from any MNN
contributing institution (ie. not only the University of Manitoba) may
submit nominations. A complete nomination consists of a letter to the
Neuroscience Awards Committee (NAC) Chair explaining the rationale for
choice of candidate, along with any supporting materials the applicant deems
useful for assessing the merit of the candidate and the benefits of his or
her visit to the University of Manitoba. Please send nominations by email
to <mailto:networking@manitobaneuroscience.ca>
networking(a)manitobaneuroscience.ca by May 1.
The NAC will determine an order of invitation priority for submitted
nominees and the top-priority candidate invited at a time determined in
consultation with the nominator. If this candidate is not available, the
next candidate will be invited. All candidates on the priority list must be
considered worthy of the Lectureship by the NAC.
We hope you find these new opportunities helpful and exciting. If there are
any questions, you may respond Dr. Chris Anderson at
<mailto:networking@manitobaneuroscience.ca>
networking(a)manitobaneuroscience.ca or <mailto:chris.anderson@umanitoba.ca>
chris.anderson(a)umanitoba.ca.
Thank you.
******************************************
<http://www.manitobaneuroscience.ca/>
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
<https://www.instagram.com/manitobaneuroscience/>
<https://twitter.com/manitobaneuro>
cid:image001.jpg@01D158FE.B69B8D00
S E M I N A R & V I S I T I N G S P E A K E R S E R I E S
D AT E
Friday, May 19th, 2017
12:00 Noon
LO C AT I O N
Theatre C
Long-Jun Wu, Ph.D.
<http://www.mayo.edu/research/faculty/wu-longjun-long-jun-ph-d/bio-20305064>
Associate Professor
Department of Neurology, Mayo Medical
School, Mayo Clinic
Topic: Microglia-neuron communication in diseased brain
(to be followed by a TRAINEE LUNCH in room SR415 **Please encourage all
your neuroscience trainees to attend!)
Microglia are the principal immune response cells in the central nervous
system. Resting microglia constantly survey the microenvironment in the
normal brain. Upon brain dysfunction, microglia are activated and exert
detrimental or beneficial effects on the surrounding neurons. However, the
molecular mechanisms for microglial activation and function in brain
diseases are still controversial. The long-term goal of my lab is to
understand microglia-neuron communication in the brain. We are interested in
fundamental questions on: (1) How microglia sense neuronal activities? (2)
How microglia regulate neuronal and synaptic function? (3) What are the
molecular mechanisms and functional consequences of microglia activation in
brain diseases? To address these questions, we use the combination of two
photon deep-brain imaging, electrophysiology, mouse genetics to dissect the
role of microglia in neuronal circuits and in brain disorders. These results
provide a novel insight on microglial function in brain emostasis and
suggest microglia as a potential therapeutic target for the treatment of
brain diseases such as epilepsy, pain and stroke.
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or
privileged information intended for a specific individual and purpose. If
you are not the intended recipient, you are hereby notified that any
disclosure, copying, retaining, distribution, access, use or modification of
the contents of this e-mailed information is strictly prohibited. If you
receive this communication in error, please notify the sender immediately
and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
cid:image007.png@01D29326.7E26D480
<https://www.instagram.com/manitobaneuroscience/>
cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro>
cid:image010.png@01D29326.7E26D480
S E M I N A R & V I S I T I N G S P E A K E R S E R I E S
D AT E
Friday, May 5th, 2017
12:00 Noon
LO C AT I O N
Apotex 071
W. Dalton Dietrich, PhD <http://www.themiamiproject.org/research/faculty/dalton-dietrich/>
Scientific Director, The Miami Project to
Cure Paralysis
Departments of Neurological Surgery,
Neurology and Biomedical Engineering,
University of Miami Miller School of Medicine, Miami
Topic: New Insights into the Pathophysiology and Treatment of Spinal Cord Injury: Current and Future Initiates
(to be followed by a TRAINEE LUNCH in room SR415 **Please encourage all your neuroscience trainees to attend!)
W. Dalton Dietrich, Ph.D., Scientific Director, The Miami Project to Cure Paralysis, Departments of Neurological Surgery, Neurology and Biomedical Engineering, University of Miami Miller School of Medicine, Miami FL USA
Each year thousands of new spinal cord injuries (SCI) occur throughout the world leading to long-term deficits and serious quality of life issues. Currently, there are millions of people living with the detrimental consequences of SCI that could benefit from reparative strategies to enhance ability and function. Although a large number of exciting preclinical studies have been conducted to test therapeutic interventions, to date no proven therapeutic modality exists that has been demonstrated to significantly improve neurological outcome. This fact emphases the need for continued research on the pathophysiology and treatment of this serious clinical condition. In the area of neuroprotection, our research programs have focused on the beneficial effects of therapeutic hypothermia on reducing multiple secondary injury mechanisms and improving outcomes. Studies conducted in multiple laboratories have now reported that mild reductions in core or spinal cord temperature early after SCI reduce overall histopathological damage and improves long-term functional outcomes. Recently, we have been successful in translating this experimental therapy to severely injured cervical SCI patients using a well described cooling and rewarming strategy. To date, we have cooled over 60 AIS A patients and at 1 year, over 43 percent of patients have converted to incomplete status (AIS B, C). A new randomized multicenter trial to assess the long-term beneficial effects of therapeutic hypothermia on sensory and motor function is now underway. In addition to acute protection, work has also emphasized the use of cell therapies and rehabilitation to improve outcomes by replacing damaged cells or producing a more permissive environment for axonal repair. We have studied the beneficial effects of autologous Schwann cell transplantation in multiple models of SCI. Schwann cell transplantation enhances axonal remyelination, growth promoting factor production and axonal regeneration. We have submitted an IND to the FDA and obtained permission to test autologous human Schwann cell transplantation in SCI. We have completed a dose escalation safety study in subacute patients with severe thoracic SCI. Based on encouraging data, we are now recruiting and transplanting Schwann cells into chronically injured spinal cord subjects that have undergone extensive rehabilitation. In addition, the benefits of neural modulation including transcranial magnetic stimulation that may act synergistically with other treatments are being assessed. Discovery and translational studies continue to provide new knowledge to fuel our future clinical studies and trials. This presentation will review progress in these areas of SCI research and other related topics.
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/>
<https://www.facebook.com/manitobaneuroscience/?fref=ts> <https://www.instagram.com/manitobaneuroscience/> <https://twitter.com/manitobaneuro>
cid:image001.jpg@01D158FE.B69B8D00
S E M I N A R & V I S I T I N G S P E A K E R S E R I E S
D AT E
Friday, May 5th, 2017
12:00 Noon
LO C AT I O N
Apotex 071
W. Dalton Dietrich, PhD
<http://www.themiamiproject.org/research/faculty/dalton-dietrich/>
Scientific Director, The Miami Project to
Cure Paralysis
Departments of Neurological Surgery,
Neurology and Biomedical Engineering,
University of Miami Miller School of Medicine, Miami
Topic: New Insights into the Pathophysiology and Treatment of Spinal Cord
Injury: Current and Future Initiates
(to be followed by a TRAINEE LUNCH in room SR415 **Please encourage all
your neuroscience trainees to attend!)
W. Dalton Dietrich, Ph.D., Scientific Director, The Miami Project to Cure
Paralysis, Departments of Neurological Surgery, Neurology and Biomedical
Engineering, University of Miami Miller School of Medicine, Miami FL USA
Each year thousands of new spinal cord injuries (SCI) occur throughout the
world leading to long-term deficits and serious quality of life issues.
Currently, there are millions of people living with the detrimental
consequences of SCI that could benefit from reparative strategies to enhance
ability and function. Although a large number of exciting preclinical
studies have been conducted to test therapeutic interventions, to date no
proven therapeutic modality exists that has been demonstrated to
significantly improve neurological outcome. This fact emphases the need for
continued research on the pathophysiology and treatment of this serious
clinical condition. In the area of neuroprotection, our research programs
have focused on the beneficial effects of therapeutic hypothermia on
reducing multiple secondary injury mechanisms and improving outcomes.
Studies conducted in multiple laboratories have now reported that mild
reductions in core or spinal cord temperature early after SCI reduce overall
histopathological damage and improves long-term functional outcomes.
Recently, we have been successful in translating this experimental therapy
to severely injured cervical SCI patients using a well described cooling and
rewarming strategy. To date, we have cooled over 60 AIS A patients and at 1
year, over 43 percent of patients have converted to incomplete status (AIS
B, C). A new randomized multicenter trial to assess the long-term beneficial
effects of therapeutic hypothermia on sensory and motor function is now
underway. In addition to acute protection, work has also emphasized the use
of cell therapies and rehabilitation to improve outcomes by replacing
damaged cells or producing a more permissive environment for axonal repair.
We have studied the beneficial effects of autologous Schwann cell
transplantation in multiple models of SCI. Schwann cell transplantation
enhances axonal remyelination, growth promoting factor production and
axonal regeneration. We have submitted an IND to the FDA and obtained
permission to test autologous human Schwann cell transplantation in SCI. We
have completed a dose escalation safety study in subacute patients with
severe thoracic SCI. Based on encouraging data, we are now recruiting and
transplanting Schwann cells into chronically injured spinal cord subjects
that have undergone extensive rehabilitation. In addition, the benefits of
neural modulation including transcranial magnetic stimulation that may act
synergistically with other treatments are being assessed. Discovery and
translational studies continue to provide new knowledge to fuel our future
clinical studies and trials. This presentation will review progress in these
areas of SCI research and other related topics.
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or
privileged information intended for a specific individual and purpose. If
you are not the intended recipient, you are hereby notified that any
disclosure, copying, retaining, distribution, access, use or modification of
the contents of this e-mailed information is strictly prohibited. If you
receive this communication in error, please notify the sender immediately
and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
cid:image007.png@01D29326.7E26D480
<https://www.instagram.com/manitobaneuroscience/>
cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro>
cid:image010.png@01D29326.7E26D480
Great news! The Manitoba Neuroscience Network was recently named 2017 best Canadian Society for Neuroscience Chapter Award for neuroscience advocacy.
http://can-acn.org/manitoba-neuroscience-network-wins-2017-can-advocacy-awa…
This is a tremendous honour for us and I want to take the opportunity to thank all faculty, trainees and admin staff who volunteer time and passion for MNN activities. You often operate behind the scenes but you are science fair judges, web/social media content coordinators, seminar and symposia organizers, expert outreach speakers, fundraisers, media liaisons, portfolio directors, event volunteers and more. Your efforts are appreciated and the fruits of your efforts are clearly recognized as outstanding at the national level.
Well done and thank you!
Chris Anderson
MNN Director
This May, Winnipeg will host the 8th International Symposium on the
Cerebellum. This is an international symposium of the Society for Research
on the Cerebellum and Ataxias and features an extensive roster of
outstanding international speakers. Several MNN scientists are members of
the local organizing committee and they wish to encourage as many Manitoba
neuroscientists as possible to register for the symposium. Please see the
following for meeting details:
Event Description: 8th International Symposium on the Cerebellum:
from Development to Disease
Location: Theatre A, Faculty of Health Sciences,
University of Manitoba; Winnipeg, Manitoba, Canada
Dates: Wednesday-Friday, May 24-26, 2017
The Program and Organizing Committees have invited internationally
recognized basic and clinical research scientists to present their
cutting-edge research on cerebellum-related topics that include: cerebellar
development genetics, functional implications, autism spectrum disorders,
ataxia, medulloblastoma, and neuroimaging with clinical approaches. We
strongly encourage participation and support from all basic and clinical
scientists that work in similar and related areas to join us for this
exciting International Conference.
The latest version of the symposium program and information is now available
online:
http://umanitoba.ca/faculties/health_sciences/medicine/units/anatomy/cerebel
lum2017.html
Abstracts may be submitted on-line until Monday, May 1st, 2017 at 11:59 p.m.
http://umanitoba.ca/faculties/health_sciences/medicine/units/anatomy/abstrac
t.html
Online Registration:
http://umanitoba.ca/faculties/health_sciences/medicine/units/anatomy/registr
ation.html
Early: October 15, 2016 - April 21, 2017
Late: April 22, 2017 - May 20, 2017
Onsite: May 24-26, 2017
For any questions regarding abstract submission or registration, please
contact us at <mailto:src2017canada@umanitoba.ca>
src2017canada(a)umanitoba.ca
Twitter: SRCA Canada
Linkedin: SRCA International Symposium
Best regards,
Local Organizing Committee
The Society for Research on the Cerebellum and Ataxia (SRCA)
Winnipeg, Manitoba, Canada, R3E 0J9
******************************************
<http://www.manitobaneuroscience.ca/>
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
<https://www.instagram.com/manitobaneuroscience/>
<https://twitter.com/manitobaneuro>
I want to provide an update about when abstracts and registrations will be accepted for the Manitoba Neuroscience Network annual scientific meeting, taking place June 16, 2017. In past years we have opened the meeting website in March. There is a delay this year because we are in the process of launching a new MNN website. Phase 1 of the website will handle SFN Winnipeg Chapter memberships and all logistics associated with the MNN annual meeting. Phase 2 will launch subsequently and will contain a rich array of content, including profiles of MNN scientists - more details about that later.
PHASE 1 is expected to launch this week or early next week. When it does, we will make an announcement. There should be plenty of time to register and submit abstracts. The ABSTRACT DEADLINE will be May 16, 2017 and the online REGISTRATION DEADLINE will be June 5, 2017. As always, reduced registration rates are available for members of the SFN Winnipeg Chapter. You will be able to become a 2017 member using the new website.
If you have any questions, please feel free to contact me, and don't forget to encourage applications by May 1 for our new MNN awards - NANCY HETTIE CLARK TRAINEE TRAVEL AWARDS and the VIKTOR HAVLICEK MEMORIAL NEUROSCIENCE LECTURESHIP.
Thank you.
Chris Anderson
MNN Director
As first announced on March 1, the MNN wishes to remind all Manitoba
scientists of our newly-created awards for trainee conference travel and a
distinguished lectureship. The deadline is May 1, 2017. Details of each
award are as follows:
NANCY HETTIE CLARK TRAINEE TRAVEL AWARDS.
Applications are now being accepted until MAY 1, 2017 for conferences taking
place between May 1, 2017 and April 30, 2018. There will normally be at
least 2 awards of $700 each, annually. The intent is for one award to go to
a Ph.D. student and the other to a postdoctoral fellow, although awards in
any trainee category can be made based on the quality and availability of
applicants.
A complete application package consists of the following, sent by email to
networking(a)manitobaneuroscience.ca
<mailto:networking@manitobaneuroscience.ca> by May 1:
* A graduate level academic transcript (students only)
* Current curriculum vitae (CV)
* Two-page (maximum) description of the research presented, the
proposed conference and the type of presentation
* Support letter from the primary research advisor with: (a) a merit
assessment of the candidate and project; and (b) confirmation that there is
a commitment to cover all eligible travel expenses less the award value
Confirmation that the abstract is accepted and will be presented will also
be required when it becomes available. Awards may be combined with other
travel awards up to but not exceeding the total cost of travel to the chosen
conference/workshop. Recipients must claim all eligible travel costs in
accordance with the appropriate policies and procedures of the University of
Manitoba.
Eligible trainees are considered to be either Ph.D. students or postdoctoral
fellows enrolled in or appointed at the University of Manitoba. Student
candidates must be enrolled as full-time Ph.D. students in the Faculty of
Graduate Studies, University of Manitoba, and have a cumulative graduate
grade point average of 3.5 or greater. Postdoctoral fellow candidates must
be within the first five years their doctoral degree and have full-time
appointments at the University of Manitoba or an affiliated hospital or
institute. Research Associates are not eligible. Candidates must
demonstrate excellent research performance and potential in a
neurosciences-related discipline. Candidates must also demonstrate they
will disseminate research results that reflect a high-quality contribution
by The University of Manitoba.
VIKTOR HAVLICEK MEMORIAL NEUROSCIENCE LECTURESHIP.
Applications are now being accepted until MAY 1, 2017 for a visit and
lecture to take place between April 1, 2018 and March 31, 2019. There will
normally be one award of $3000, made biannually. Applications for the next
Lectureship will be accepted in 2019 for 2020/2021 fiscal year.
Nominations must be made by a faculty member but trainees and staff are
encouraged to suggest names to their advisors. Faculty from any MNN
contributing institution (ie. not only the University of Manitoba) may
submit nominations. A complete nomination consists of a letter to the
Neuroscience Awards Committee (NAC) Chair explaining the rationale for
choice of candidate, along with any supporting materials the applicant deems
useful for assessing the merit of the candidate and the benefits of his or
her visit to the University of Manitoba. Please send nominations by email
to <mailto:networking@manitobaneuroscience.ca>
networking(a)manitobaneuroscience.ca by May 1.
The NAC will determine an order of invitation priority for submitted
nominees and the top-priority candidate invited at a time determined in
consultation with the nominator. If this candidate is not available, the
next candidate will be invited. All candidates on the priority list must be
considered worthy of the Lectureship by the NAC.
We hope you find these new opportunities helpful and exciting. If there are
any questions, you may respond Dr. Chris Anderson at
<mailto:networking@manitobaneuroscience.ca>
networking(a)manitobaneuroscience.ca or <mailto:chris.anderson@umanitoba.ca>
chris.anderson(a)umanitoba.ca.
Thank you.
******************************************
<http://www.manitobaneuroscience.ca/>
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
<https://www.instagram.com/manitobaneuroscience/>
<https://twitter.com/manitobaneuro>
Dr. Kleims visit to Winnipeg has been cancelled due to a family emergency.
Therefore, the lecture and trainee lunch scheduled for Thursday Apr 6th have
both been cancelled.
Kelly
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: <mailto:kjorund@sbrc.ca> kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or
privileged information intended for a specific individual and purpose. If
you are not the intended recipient, you are hereby notified that any
disclosure, copying, retaining, distribution, access, use or modification of
the contents of this e-mailed information is strictly prohibited. If you
receive this communication in error, please notify the sender immediately
and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
cid:image007.png@01D29326.7E26D480
<https://www.instagram.com/manitobaneuroscience/>
cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro>
cid:image010.png@01D29326.7E26D480
cid:image001.jpg@01D158FE.B69B8D00
V I S I T I N G S P E A K E R & S E M I N A R S E R I E S
S P E A K E R
JEFFREY KLEIM, PH.D
<https://sbhse.engineering.asu.edu/faculty-and-staff/faculty/jeff-kleim/>
Associate Director
School of Biological and Health Systems Engineering
Arizona State University
D AT E
Thursday, April 6th, 2017
NEUROSCIENCE TRAINEE LUNCH 12:00 NOON
12:00 Noon | SR415 Kleysen Institute for Advanced Medicine
*ALL NEUROSCIENCE TRAINEES INVITED!
D AT E
Thursday, April 6th, 2017
RESEARCH LECTURE 3:00 PM
TOPIC: Neural Plasticity and Neurorehabilitation: Encouraging the Brain to
Change
3:00PM | Theatre C
Abstract: The capacity for the nervous system to structurally and
functionally adapt (neural plasticity) has been described for more than a
century. Decades of neuroanatomical, neurophysiological and molecular
studies have revealed that neural plasticity is an evolutionarily conserved,
fundamental property of all
nervous tissue. It is critical for maintaining normal brain function and yet
can also manifest into various forms of brain dysfunction. While we still do
not fully understand the complexity of the human nervous system, its
response to disease/injury and capacity for recovery, treatments designed to
harness endogenous neural plasticity to overcome neurological impairment
continue to emerge. Specifically, the characterization of key behavioral and
neurobiological signals that drive neural plasticity, in combination with
advances in biomedical engineering, regenerative medicine and genomics, have
created opportunities to develop novel therapeutic interventions. Evidence
from both animal and clinical studies will be presented that demonstrate how
modulating specific elements of motor rehabilitation can enhance functional
outcome and cortical reorganization after stroke. Further, the viability of
many adjuvant therapies for augmenting neural plasticity to enhance the
impact of motor rehabilitation will be presented.
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: <mailto:kjorund@sbrc.ca> kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or
privileged information intended for a specific individual and purpose. If
you are not the intended recipient, you are hereby notified that any
disclosure, copying, retaining, distribution, access, use or modification of
the contents of this e-mailed information is strictly prohibited. If you
receive this communication in error, please notify the sender immediately
and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
cid:image007.png@01D29326.7E26D480
<https://www.instagram.com/manitobaneuroscience/>
cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro>
cid:image010.png@01D29326.7E26D480